Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

Zilan Song, Meining Wang, Ao Zhang, Zilan Song, Meining Wang, Ao Zhang

Abstract

The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry. The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing. Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed through a variety of mechanisms. In addition to ceritinib, alectinib is another second-generation ALK inhibitor launched in 2014 in Japan. This drug has a unique chemical structure bearing a 5H-benzo[b]carbazol-11(6H)-one structural scaffold with an IC50 value of 1.9 nmol/L, and is highly potent against ALK bearing the gatekeeper mutation L1196M with an IC50 of 1.56 nmol/L. In the clinic, alectinib is highly efficacious in treatment of ALK-positive non-small cell lung cancer (NSCLC), and retains potency to combat crizotinib-resistant ALK mutations L1196M, F1174L, R1275Q and C1156Y.

Keywords: ALK mutations; Alectinib; Crizotinib; EML4-ALK; Non-small cell lung cancer; Resistance; Tyrosine anaplastic lymphoma kinase.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Chemical structures of approved ALK inhibitors.
Figure 2
Figure 2
ALK is on the high-speed train.

References

    1. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin׳s lymphoma. Science. 1994;263:1281–1284.
    1. Rikova K., Guo A.L., Zeng Q.F., Possemato A., Yu J., Haack H. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203.
    1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
    1. Roskoski R., Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68:68–94.
    1. Shaw A.T., Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17:2081–2086.
    1. Gridelli C., Peters S., Sgambato A., Casaluce F., Adjei A.A., Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014;40:300–306.
    1. Cui J.J., Tran-Dubé M., Shen H., Nambu M., Kung P.P., Pairish M. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal−epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J Med Chem. 2011;54:6342–6363.
    1. Cui J.J., McTigue M., Kania R., Edwards M.P. Case history: Xalkori™ (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment. Ann Rep Med Chem. 2013;48:421–432.
    1. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–1012.
    1. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–1482.
    1. Kinoshita K., Oikawa N., Tsukuda T. Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers. Ann Rep Med Chem. 2012;47:281–293.
    1. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734–1739.
    1. Ramalingam S., Khuri F.P. Second generation ALK inhibitors: filling the non ‘MET’ gap. Cancer Disc. 2014;4:634–636.
    1. Wang W.C., Shiao H.Y., Lee C.C., Fung K.S., Hsieh H.P. Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. Med Chem Commun. 2014;5:1266–1279.
    1. Awad M.M., Shaw A.T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12:429–439.
    1. Marsilje T.H., Pei W., Chen B., Lu W., Uno T., Jin Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56:5675–5690.
    1. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–1197.
    1. Latif M., Saeed A., Kim S.H. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Arch Pharm Res. 2013;36:1051–1054.
    1. Kinoshita K., Kobayashi T., Asoh K., Furuichi N., Ito T., Kawada H. 9-Substituted 6, 6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J Med Chem. 2011;54:6286–6294.
    1. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19:679–690.
    1. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14:590–598.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir